Iovance Biotherapeutics (IOVA) Current Leases (2019 - 2026)

Iovance Biotherapeutics (IOVA) has reported Current Leases for 8 consecutive years, with $2.9 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Current Leases fell 65.89% year-over-year to $2.9 million; the TTM figure through Mar 2026 stood at $2.9 million (down 65.89% YoY), while the FY2025 annual figure was $4.0 million, down 68.65% from the prior year.
• Current Leases retreated to $2.9 million in Q1 2026 per IOVA's latest filing, from $4.0 million in the prior quarter.
• Across five years, Current Leases topped out at $12.9 million in Q4 2024 and bottomed at $2.9 million in Q1 2026.
• Historically, Current Leases has averaged $8.6 million across 5 years, with a median of $7.8 million in 2023.
• Annual changes were most pronounced in 2022 — Current Leases surged 148.9% — and 2025, when it plunged 68.65%.
• Iovance Biotherapeutics' Current Leases stood at $12.6 million in 2022, then sank by 38.21% to $7.8 million in 2023, then soared by 65.82% to $12.9 million in 2024, then slumped by 68.65% to $4.0 million in 2025, then slipped by 28.3% to $2.9 million in 2026.
• Business Quant data shows IOVA's Current Leases at $2.9 million in Q1 2026, $4.0 million in Q4 2025, and $6.3 million in Q3 2025.